NCT00585000 - A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Melanoma

Interventions

DRUG

CP-675,206

15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.

Trial Locations (8)

27710

Research Site, Durham

30322

Research Site, Atlanta

40202

Research Site, Louisville

46202

Research Site, Indianapolis

80045

Research Site, Aurora

85258

Research Site, Scottsdale

90095

Research Site, Los Angeles

90095-7423

Research Site, Los Angeles